Publications by authors named "Orsolya Modos"

Claim this Profile
E
Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.
Melinda Váradi, Orsolya Horváth, Orsolya Módos, Tamás Fazekas, Camilla M Grunewald

Sci Rep· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Melinda Varadi, Nikolett Nagy, Henning Reis, Boris Hadaschik, Christian Niedworok, Orsolya Modos

Cancer Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Current diagnostic and treatment strategies for urachal cancer].
Orsolya Módos, Melinda Váradi, Bálint Dér, Attila Keszthelyi, Miklós Szűcs

Orv Hetil· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.
Dávid Keresztes, Anita Csizmarik, Nikolett Nagy, Orsolya Módos, Tamás Fazekas

J Cell Mol Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy.
Ulrich Krafft, Csilla Olah, Henning Reis, Claudia Kesch, Christopher Darr, Orsolya Modos

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of APC and PTEN Alterations in Urachal Cancer.
Nikolett Nagy, Henning Reis, Boris Hadaschik, Christian Niedworok, Orsolya Módos

Pathol Oncol Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients.
Csilla Olah, Stephan Tschirdewahn, Michèle J Hoffmann, Ulrich Krafft, Boris Hadaschik

Diagnostics (Basel)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Characteristics of bladder recurrence after radical nephroureterectomy in upper urinary tract cancer].
Petra Terézia Kovács, Dániel Juhász, Orsolya Módos, Ildikó Kocsmár, András Terebessy

Orv Hetil· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.
Ulrich Krafft, Stephan Tschirdewahn, Jochen Hess, Nina N Harke, Boris Hadaschik

Urol Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
Henning Reis, Kristan E van der Vos, Christian Niedworok, Thomas Herold, Orsolya Módos

Int J Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
Tibor Szarvas, Sabina Sevcenco, Orsolya Módos, Dávid Keresztes, Péter Nyirády

BJU Int· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.
Henning Reis, Ulrich Krafft, Christian Niedworok, Orsolya Módos, Thomas Herold

Dis Markers· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
Tibor Szarvas, Sabina Sevcenco, Orsolya Módos, Dávid Keresztes, Péter Nyirády

Urol Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why are upper tract urothelial carcinoma two different diseases?
Tibor Szarvas, Orsolya Módos, András Horváth, Péter Nyirády

Transl Androl Urol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases.
Tibor Szarvas, Orsolya Módos, Christian Niedworok, Henning Reis, Attila Szendröi

Urol Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis.
Christian Niedworok, Martin Panitz, Tibor Szarvas, Henning Reis, Anna Carinna Reis

J Urol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Orsolya Módos, Henning Reis, Christian Niedworok, Herbert Rübben, Attila Szendröi

Oncotarget· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis